- Home
- VSTA vs CHRS Comparison
VSTA vs CHRS Comparison
Compare VSTA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTA
- CHRS
- Stock Information
- Founded
- VSTA 1966
- CHRS 2010
- Country
- VSTA Brazil
- CHRS United States
- Employees
- VSTA N/A
- CHRS N/A
- Industry
- VSTA Other Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTA Real Estate
- CHRS Health Care
- Exchange
- VSTA Nasdaq
- CHRS Nasdaq
- Market Cap
- VSTA 332.9M
- CHRS 84.2M
- IPO Year
- VSTA 2020
- CHRS 2014
- Fundamental
- Price
- VSTA $4.25
- CHRS $0.82
- Analyst Decision
- VSTA Sell
- CHRS Buy
- Analyst Count
- VSTA 2
- CHRS 3
- Target Price
- VSTA $3.00
- CHRS $4.68
- AVG Volume (30 Days)
- VSTA 27.4K
- CHRS 1.3M
- Earning Date
- VSTA 08-06-2025
- CHRS 08-07-2025
- Dividend Yield
- VSTA N/A
- CHRS N/A
- EPS Growth
- VSTA N/A
- CHRS N/A
- EPS
- VSTA 1.00
- CHRS N/A
- Revenue
- VSTA $286,712,653.00
- CHRS $272,251,000.00
- Revenue This Year
- VSTA $14.62
- CHRS N/A
- Revenue Next Year
- VSTA $10.84
- CHRS $106.56
- P/E Ratio
- VSTA $4.26
- CHRS $1.87
- Revenue Growth
- VSTA 6.46
- CHRS 19.87
- 52 Week Low
- VSTA $1.60
- CHRS $0.66
- 52 Week High
- VSTA $5.49
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VSTA 50.97
- CHRS 53.13
- Support Level
- VSTA $4.15
- CHRS $0.72
- Resistance Level
- VSTA $4.29
- CHRS $0.77
- Average True Range (ATR)
- VSTA 0.15
- CHRS 0.04
- MACD
- VSTA 0.00
- CHRS 0.01
- Stochastic Oscillator
- VSTA 39.02
- CHRS 91.62
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.